NASDAQ:HALO

Halozyme Therapeutics (HALO) Stock Forecast, Price & News

$37.53

-0.67 (-1.75%)

(As of 02:45 PM ET)

Compare

Today's Range: $37.30
▼
$38.20
50-Day Range: $37.50
▼
$44.03
52-Week Range: $29.85
▼
$59.46

Volume: 344,390 shs
Average Volume: 1.25 million shs
Market Capitalization: $4.95 billion

P/E Ratio: 21.95
Dividend Yield: N/A
Price Target: $54.27

Halozyme Therapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.73 Rating Score
Upside/Downside: 45.2% Upside
$54.27 Price Target
Short Interest: Bearish
5.24% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.12
Upright™ Environmental Score
News Sentiment: 1.04
Based on 5 Articles This Week
Insider Trading: Selling Shares
$4.23 M Sold Last Quarter
Proj. Earnings Growth: 44.35%
From $2.48 to $3.58 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.95 out of 5 stars

Medical Sector

34th out of 969 stocks

Biological Products, Except Diagnostic Industry

3rd out of 161 stocks

3.4

Analyst's Opinion

Consensus Rating
Halozyme Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on 8 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $54.27, Halozyme Therapeutics has a forecasted upside of 45.2% from its current price of $37.37.
Amount of Analyst Coverage
Halozyme Therapeutics has only been the subject of 3 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
5.24% of the float of Halozyme Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Halozyme Therapeutics has a short interest ratio ("days to cover") of 6.9.
Change versus previous month

0.0

Dividend Strength

Dividend Yield
Halozyme Therapeutics does not currently pay a dividend.
Dividend Growth
Halozyme Therapeutics does not have a long track record of dividend growth.

4.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Halozyme Therapeutics has received a 65.83% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Biopharmaceuticals" and "Medical technology engineering" products. See details.
Environmental Sustainability
The Environmental Impact score for Halozyme Therapeutics is -1.12.

2.8

News and Social Media Coverage

News Sentiment
Halozyme Therapeutics has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Halozyme Therapeutics this week, compared to 4 articles on an average week.
Search Interest
Only 3 people have searched for HALO on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.
MarketBeat Follows
Only 6 people have added Halozyme Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Halozyme Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,228,900.00 in company stock.
Percentage Held by Insiders
Only 2.40% of the stock of Halozyme Therapeutics is held by insiders.
Percentage Held by Institutions
92.59% of the stock of Halozyme Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

4.4

Earnings and Valuation

Earnings Growth
Earnings for Halozyme Therapeutics are expected to grow by 44.35% in the coming year, from $2.48 to $3.58 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Halozyme Therapeutics is 21.85, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 111.60.
Price to Earnings Ratio vs. Sector
The P/E ratio of Halozyme Therapeutics is 21.85, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 100.60.
Price to Earnings Growth Ratio
Halozyme Therapeutics has a PEG Ratio of 0.59. PEG Ratios below 1 indicate that a company could be undervalued.
Price to Book Value per Share Ratio
Halozyme Therapeutics has a P/B Ratio of 29.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Halozyme Therapeutics (NASDAQ:HALO) Stock

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; NOCDURNA, a sublingual tablet to treat nocturia due to nocturnal polyuria; TLANDO, an oral formulation for testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of multiple blood cancer; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergy and immunology; Sumatriptan injection for migraines; exenatide and teriparatide injections; Makena, a progestin drug to reduce the risk of preterm birth; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

HALO Price History

30 days | 90 days | 365 days | Advanced Chart

HALO Stock News Headlines

September 26, 2023 | americanbankingnews.com

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Rating of "Moderate Buy" by Brokerages

September 20, 2023 | finance.yahoo.com

Insider Sell: SVP, Chief Technical Officer Michael Labarre Sells 10,000 Shares of Halozyme ...

October 2, 2023 | UNKNOWN (Ad)

First-In-Class Pharmaceutical Therapies

Biopharma Company That Is Leading the Way in Eye Care Advancements

September 12, 2023 | msn.com

Halozyme: Intriguing Buy Prospect Despite This Week's PDUFA Setback

September 12, 2023 | finance.yahoo.com

ReNAgade Therapeutics Appoints Laurie Stelzer as Chief Financial Officer

September 7, 2023 | finance.yahoo.com

Halozyme Therapeutics (HALO) Down 3.8% Since Last Earnings Report: Can It Rebound?

September 5, 2023 | finance.yahoo.com

Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock

September 1, 2023 | finance.yahoo.com

Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term

October 2, 2023 | UNKNOWN (Ad)

First-In-Class Pharmaceutical Therapies

Biopharma Company That Is Leading the Way in Eye Care Advancements

August 31, 2023 | msn.com

HC Wainwright & Co. Reiterates Halozyme Therapeutics (HALO) Buy Recommendation

August 30, 2023 | finance.yahoo.com

Should You Remain Confident in Halozyme Therapeutics (HALO)?

August 29, 2023 | finance.yahoo.com

Halozyme Announces Approval of Roche's Tecentriq® Subcutaneous (SC) with ENHANZE® in Great Britain

August 15, 2023 | msn.com

HC Wainwright & Co. Maintains Halozyme Therapeutics (HALO) Buy Recommendation

August 15, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Their Buy Rating for Halozyme (HALO)

August 15, 2023 | markets.businessinsider.com

Expert Ratings for Halozyme Therapeutics

August 10, 2023 | seekingalpha.com

Halozyme Therapeutics, Inc. (HALO) Q2 2023 Earnings Call Transcript

August 9, 2023 | finance.yahoo.com

Halozyme (HALO) Q2 Earnings & Revenues Beat, 2023 View Raised

August 9, 2023 | markets.businessinsider.com

Goldman Sachs Sticks to Its Hold Rating for Halozyme (HALO)

August 9, 2023 | finance.yahoo.com

Compared to Estimates, Halozyme Therapeutics (HALO) Q2 Earnings: A Look at Key Metrics

August 8, 2023 | msn.com

Halozyme Therapeutics Non-GAAP EPS of $0.74 beats by $0.10, revenue of $221.04M beats by $21.09M

August 8, 2023 | finance.yahoo.com

HALOZYME REPORTS SECOND QUARTER 2023 FINANCIAL AND OPERATING RESULTS

August 8, 2023 | finance.yahoo.com

Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Top Estimates

August 8, 2023 | seekingalpha.com

Halozyme Therapeutics Q2 2023 Earnings Preview

July 28, 2023 | reuters.com

Focus: Drugmakers go under the skin, skirting early US Medicare price negotiations

July 25, 2023 | finance.yahoo.com

Halozyme To Report Second Quarter 2023 Financial and Operating Results

July 25, 2023 | nasdaq.com

HC Wainwright & Co. Initiates Coverage of Halozyme Therapeutics (HALO) with Buy Recommendation

July 25, 2023 | msn.com

Goldman Sachs Downgrades Halozyme Therapeutics (HALO)

See More Headlines

Receive HALO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Halozyme Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

HALO Company Calendar

Last Earnings: 8/08/2023
Today: 10/02/2023
Next Earnings (Estimated): 11/14/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:HALO
CUSIP: 40637H10
CIK: 1159036
Web: www.halozyme.com
Phone: 858-794-8889
Fax: 858-704-8311
Employees: 393
Year Founded: 1998

Price Target and Rating

Average Stock Price Forecast: $54.27
High Stock Price Forecast: $68.00
Low Stock Price Forecast: $42.00
Forecasted Upside/Downside: +42.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.73
Research Coverage: 11 Analysts

Profitability

EPS (Most Recent Fiscal Year): $1.71
Trailing P/E Ratio: 22.34
Forward P/E Ratio: 15.40
P/E Growth: 0.59
Net Income: $202.13 million
Net Margins: 30.21%
Pretax Margin: 37.47%
Return on Equity: 254.75%
Return on Assets: 17.08%

Debt

Debt-to-Equity Ratio: 9.91
Current Ratio: 6.58
Quick Ratio: 5.44

Sales & Book Value

Annual Sales: $660.12 million
Price / Sales: 7.63
Cash Flow: $2.59 per share
Price / Cash Flow: 14.73
Book Value: $1.26 per share
Price / Book: 30.32

Miscellaneous

Outstanding Shares: 131,920,000
Free Float: 128,755,000
Market Cap: $5.04 billion
Optionable: Optionable
Beta: 1.24

Social Links

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Dr. Helen I. Torley M.B. Ch. B. (Age 60)
M.R.C.P., Pres, CEO & Director
Comp: $1.45M

Ms. Nicole LaBrosse (Age 40)
Sr. VP & CFO
Comp: $727.04k

Dr. Michael J. LaBarre Ph.D. (Age 59)
Sr. VP & Chief Technical Officer
Comp: $723.24k

Mr. Mark Snyder Esq.
Chief Legal Officer

Ms. Tram Bui
Head of Investor Relations & Corp. Communications

Ms. Amy Marinne Fox
Chief HR Officer

Dr. Steve Knowles MBBS
Chief Medical Officer

Dr. Christopher Bryant Ph.D. (Age 62)
Chief Manufacturing Officer & Head of Technical Operations

Ms. Kristin Schwartzbauer
Head of Quality

Mr. Gary Grote
Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

HALO Stock - Frequently Asked Questions

Should I buy or sell Halozyme Therapeutics stock right now?: 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last twelve months. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" HALO shares.
View HALO analyst ratings or view top-rated stocks.
What is Halozyme Therapeutics' stock price forecast for 2023?: 11 brokerages have issued 12 month target prices for Halozyme Therapeutics' stock. Their HALO share price forecasts range from $42.00 to $68.00. On average, they expect the company's share price to reach $54.27 in the next year. This suggests a possible upside of 42.1% from the stock's current price.
View analysts price targets for HALO or view top-rated stocks among Wall Street analysts.
How have HALO shares performed in 2023?: Halozyme Therapeutics' stock was trading at $56.90 on January 1st, 2023. Since then, HALO stock has decreased by 32.9% and is now trading at $38.20.
View the best growth stocks for 2023 here.
When is Halozyme Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our HALO earnings forecast.
How were Halozyme Therapeutics' earnings last quarter?: Halozyme Therapeutics, Inc. (NASDAQ:HALO) released its quarterly earnings results on Tuesday, August, 8th. The biopharmaceutical company reported $0.68 EPS for the quarter, topping analysts' consensus estimates of $0.59 by $0.09. The biopharmaceutical company had revenue of $221.04 million for the quarter, compared to analysts' expectations of $201.91 million. Halozyme Therapeutics had a net margin of 30.21% and a trailing twelve-month return on equity of 254.75%.
What ETFs hold Halozyme Therapeutics' stock?: ETFs with the largest weight of Halozyme Therapeutics (NASDAQ:HALO) stock in their portfolio include Future Fund Long/Short ETF (FFLS), Future Fund Active ETF (FFND), Invesco Biotechnology & Genome ETF (PBE), Virtus LifeSci Biotech Products ETF (BBP), BlackRock Future Innovators ETF (BFTR), Invesco S&P MidCap 400 Pure Growth ETF (RFG), SPDR S&P Biotech ETF (XBI) and Goldman Sachs Future Health Care Equity ETF (GDOC).
What guidance has Halozyme Therapeutics issued on next quarter's earnings?: Halozyme Therapeutics issued an update on its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided earnings per share (EPS) guidance of $2.65-$2.75 for the period, compared to the consensus earnings per share estimate of $2.61. The company issued revenue guidance of $825.00 million-$845.00 million, compared to the consensus revenue estimate of $823.06 million.
What is Helen Torley's approval rating as Halozyme Therapeutics' CEO?: 12 employees have rated Halozyme Therapeutics Chief Executive Officer Helen Torley on Glassdoor.com. Helen Torley has an approval rating of 75% among the company's employees.

What other stocks do shareholders of Halozyme Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Halozyme Therapeutics investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Micron Technology (MU), Gilead Sciences (GILD), Athabasca Oil (ATH), NIC (EGOV), Allergan (AGN) and AbbVie (ABBV).
What is Halozyme Therapeutics' stock symbol?: Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO."
How do I buy shares of Halozyme Therapeutics?: Shares of HALO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Halozyme Therapeutics' stock price today?: One share of HALO stock can currently be purchased for approximately $38.20.
How much money does Halozyme Therapeutics make?: Halozyme Therapeutics (NASDAQ:HALO) has a market capitalization of $5.04 billion and generates $660.12 million in revenue each year. The biopharmaceutical company earns $202.13 million in net income (profit) each year or $1.71 on an earnings per share basis.
How many employees does Halozyme Therapeutics have?: The company employs 393 workers across the globe.
Does Halozyme Therapeutics have any subsidiaries?: The following companies are subsidiares of Halozyme Therapeutics: Halozyme Holdings Ltd., Halozyme Inc., Halozyme Switzerland GmbH, and Halozyme Switzerland Holdings GmbH.
Read More
How can I contact Halozyme Therapeutics?: Halozyme Therapeutics' mailing address is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121-1345. The official website for the company is www.halozyme.com. The biopharmaceutical company can be reached via phone at 858-794-8889, via email at ir@halozyme.com, or via fax at 858-704-8311.

This page (NASDAQ:HALO) was last updated on 10/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial